Clinical data | |
---|---|
Other names | 19-Normegestrol; 6-Methyl-17α-hydroxy-δ6-19-norprogesterone; 17α-Hydroxy-6-methyl-19-norpregna-4,6-diene-3,20-dione |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C21H28O3 |
Molar mass | 328.452 g·mol−1 |
3D model (JSmol) | |
| |
|
Nomegestrol (INN ), also known as 19-normegestrol, is a steroidal progestin which was patented in 1975 but was never marketed.[1][2] It is the parent compound of nomegestrol acetate, which is marketed as a progestin.[1][2]
Nomegestrol shows relatively low affinity for the progesterone receptor, only about 4% of that of progesterone and about 1.6% of that of nomegestrol acetate in one assay.[3]